Skye Bioscience, Inc.
SKYE
$0.72
$0.068.39%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -55.92M | -51.23M | -42.37M | -32.65M | -26.57M |
| Total Depreciation and Amortization | 723.40K | 718.70K | 605.80K | 448.50K | 298.70K |
| Total Amortization of Deferred Charges | -- | 0.00 | 111.50K | 361.80K | 599.00K |
| Total Other Non-Cash Items | 7.41M | 8.24M | 3.79M | 3.93M | 3.06M |
| Change in Net Operating Assets | 4.73M | 805.80K | 4.50M | -1.80M | -2.63M |
| Cash from Operations | -43.06M | -41.47M | -33.37M | -29.71M | -25.24M |
| Capital Expenditure | -6.30K | -56.30K | -1.57M | -1.61M | -1.60M |
| Sale of Property, Plant, and Equipment | 360.80K | 321.20K | 302.60K | 213.20K | 1.36M |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -19.85M | -16.87M | -24.75M | -12.80M | -- |
| Cash from Investing | -19.50M | -16.61M | -26.02M | -14.20M | -245.60K |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | 6.44M | 6.44M | 6.44M | 92.09M |
| Repurchase of Common Stock | -- | -- | -- | -2.10M | -2.10M |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 29.60K | -6.42M | -6.42M | -6.43M | -6.43M |
| Cash from Financing | 29.60K | 23.80K | 23.80K | -2.09M | 83.56M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -62.53M | -58.05M | -59.36M | -46.00M | 58.08M |